Shares of Wockhardt extended their rally for a second straight trading session on Tuesday, buoyed by renewed investor optimism after the company announced a regulatory milestone for its novel antibiotic, Zaynich.
The stock traded firmly in positive territory through the day, with strong volumes indicating sustained bullish sentiment.
The surge comes after Wockhardt revealed on Monday that the USFDA has accepted the New Drug Application (NDA) for Zaynich, antibiotic developed by the company.
The drug has also received fast-track designation from the US regulator, underscoring its potential to address urgent and unmet medical needs, particularly in the realm of resistant bacterial infections.
On Monday, the stock rallied over 20 per cent. It zoomed 6.5 per cent on Tuesday to 1,566.95 against the previous close of 1,470.90. At 9.56 am, it traded 6 per cent higher at ₹1562.50 on the BSE.
Published on December 2, 2025
